Class III Device Recalls An Afterthought? Not So Fast . . .
This article was originally published in The Silver Sheet
Executive Summary
Low-risk class III medical device recalls sometimes fade into the background because they comprise only a sliver of the overall corrections and removals in a given year. Nevertheless, manufacturers should be aware that any decisions they make regarding class III actions are still going to receive FDA attention. One example: “The justification for not reporting a recall is an area that the agency frequently takes a very close look at,” CDRH Recall Branch Chief Ron Brown says. When FDA wrote its recalls regulation it left the decision about whether to report class III events up to manufacturers. Reporting such low-risk recalls is not required by the agency, but is obviously encouraged if firms discover that the risk to device users is somewhat significant. Such a gray area can leave firms wondering about when it’s necessary to report class III’s – or even whether they should be reported in the first place.
You may also be interested in...
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.
FDA Slaps High Risk Class I Label On Recall Of COVID-19 Diagnostics Made In Uncontrolled Plant
More than 160,000 of the tests were recalled, including 104,900 COVID Test Kits Nonsterile and 61,500 Clean Catch Urine Kits.